(Credit-okuntakinte/Instagram)
This is the story of Joseph, a 28-year-old man who's made a very difficult choice. On December 2024, Joseph Awuah-Darko shared the difficult decision of choosing euthanasia on Instagram. He's not physically sick, but he's been battling a severe mental illness called bipolar disorder for many years. He's tried many treatments, but nothing has helped him feel better. He feels like the pain of his illness is too much to bear. He's shared his story publicly to help people understand what he's going through and to show how serious mental illness can be. Joseph shared a post that explained why he is making this decision, in the caption of the post he shared, “I am not saying that life (as a phenomenon) isn’t worth living. It ABSOLUTELY is. What I am saying is that the mental weight of MINE has become entirely unbearable.”
Joseph has bipolar disorder, which means his moods swing very high and very low. He's had this illness for a long time, and it makes his life very difficult. On his Instagram, he has shared his journey with bipolar, he explained that he tried many different medicines and therapies, but they haven't worked. He feels constant pain and suffering because of his illness. He's reached a point where he feels like he can't go on anymore. He's been open about his struggles on social media, hoping to raise awareness about mental health. He wants people to understand how much he suffers and why he's made this decision.
Government of the Netherlands explain that in the Netherlands, it's legal for a doctor to help someone end their life if they meet certain conditions. This is called euthanasia. Joseph has applied for this because he feels his mental illness is causing him unbearable suffering. There are rules and procedures that doctors must follow. They have to make sure the person understands their decision and that there are no other options. The process can take a long time, sometimes years. Joseph believes that having the option of a peaceful and dignified death is important. He wants to have control over how his life ends.
When Joseph shared his decision, people had many different reactions. Some people understood and supported him. Others were sad and hoped he would change his mind. He even received some negative comments. But he also received many kind messages, including invitations to have dinner. This inspired him to start "The Last Supper Project," where he travels and shares meals with strangers. In the caption he explained, “‘The Last Supper Project’ is based on the Harvard Study of Adult Development which speaks to the importance of quality relationships and community as the greatest predictor for happiness. And I feel connecting this way around food as a great unifying vessel could be beautiful.”
The Last Supper Project is one of the longest studies, lasting for more than 80 years, done on adult development. In an Author Speaks edition of McKinsey & Company, the study’s director Robert Waldinger explained the study wanted to know what helps people have happy and healthy lives, even if they had problems when they were young. Most studies only looked at what goes wrong, but this one wanted to know what goes right. The study emphasizes that it is never too late for positive changes. People often believe they are too old or incapable of forming good relationships. They may think happiness is out of reach. However, the study has observed individuals who found happiness unexpectedly.
Joseph wants to connect with people and enjoy these moments while he waits for his euthanasia request to be approved. He sees these dinners as a way to find joy and connection in his final chapter. He still has bad days, but he finds comfort in these shared experiences.
Credits: Canva
A newly recognised form of diabetes is reshaping how scientists and doctors view the condition, particularly in countries like India. In 2025, global health authorities officially acknowledged Type 5 diabetes as a separate and distinct form of the disease.
This recognition ended decades of confusion around a type of diabetes that did not fit neatly into the existing categories of Type 1 or Type 2 diabetes. The formal classification, backed by the International Diabetes Federation and supported by research published in The Lancet Global Health, is expected to transform diagnosis, treatment, and long-term care for millions of people worldwide.
But what exactly is Type 5 diabetes, and how does it differ from the types of diabetes that are more widely known?
Type 5 diabetes is now recognised as a distinct form of the disease caused primarily by severe, long-term malnutrition, often experienced during childhood. This undernutrition can lead to profound insulin deficiency and an underdeveloped pancreas, resulting in significantly reduced insulin production.
Unlike Type 1 diabetes, which is autoimmune, or Type 2 diabetes, which is linked to insulin resistance, Type 5 diabetes arises from nutritional deficiencies that impair the pancreas’s ability to function properly.
It most commonly affects lean young adults in low-income regions. For years, people with this condition were misdiagnosed as having Type 1 diabetes or an unusual form of Type 2, often leading to inappropriate treatments that failed to address the root cause.
Symptoms of type 5 diabetes can resemble those seen in other forms of diabetes, such as excessive thirst, frequent urination, persistent tiredness, unexplained weight loss, blurred vision, and slow-healing wounds. However, they are often paired with indications of malnutrition, including a lean physique, delayed growth or puberty in young people, anemia, and recurring infections.
These arise from nutritional deficiencies during early life rather than solely from insulin resistance or autoimmune causes, and they usually present before the age of 30, according to the International Diabetes Federation.
Researchers have been studying this condition for decades, particularly in parts of Asia and Africa. Yet, without official recognition, the disease remained poorly understood, and patients were rarely diagnosed correctly. Experts argued that grouping these patients under existing categories obscured the true cause of their illness.
The 2025 classification now formally separates Type 5 diabetes from other types, making it easier to study, identify, and manage. In India, where diabetes prevalence is already high, this recognition is particularly relevant. Tens of millions of people live with diabetes in the country, many of whom remain undiagnosed. Type 5 diabetes highlights a different pattern: it develops not from excess calories, but from too little nutrition during childhood, creating a double burden in regions where obesity and undernutrition coexist.
Although there is no new treatment specifically for Type 5 diabetes yet, official recognition marks a major step forward. Doctors can now approach lean patients with a history of malnutrition more carefully, avoiding a “one-size-fits-all” approach. Clearer classification could lead to better guidelines, more personalised care, fewer complications, and improved long-term outcomes.
Experts believe that understanding the role of childhood undernutrition in diabetes could eventually reshape how we prevent, monitor, and manage the condition—something countries like India urgently need as diabetes numbers continue to rise.
Credits: Canva
An early sign of dementia can sometimes look like a common winter-related issue. When this symptom appears along with other warning signals, it may be wise to speak to a doctor. Dementia is a syndrome marked by a collection of related symptoms that point to a gradual decline in brain function. Over time, this can affect memory, behaviour, thinking, and even movement. In its early phase, however, dementia often shows up through subtle changes that are easy to overlook or mistake for something less serious.
Dementia UK notes that one possible early indicator of dementia is “low mood, anxiety or depression”. Its specialists explain: “In the early stages of dementia, people often begin to notice symptoms that interfere with day-to-day life.” The difficulty is that low mood or depression can also be linked to seasonal affective disorder (SAD), a form of depression that tends to appear during winter and ease as the days become longer and brighter.
The NHS lists the following possible symptoms of SAD:
The organisation explains: “A person experiencing early symptoms of dementia may notice these changes themselves, or they may be picked up first by family members, friends or colleagues. Memory problems are not always obvious in the early stages of some types of dementia, such as frontotemporal dementia, where changes in behaviour and personality may appear first.
“People with young onset dementia, where symptoms begin before the age of 65, are also less likely to have memory loss as an early symptom.”
The charity also points out that emotional changes can be linked to two specific types of dementia. In vascular dementia, a person may experience “changes in mood, behaviour and personality”, while Lewy body dementia can cause “mood changes, including anxiety and depression”.
That said, it is often difficult to know at first whether dementia is the cause of these warning signs. Dementia UK advises: “Many symptoms associated with dementia can also be caused by other physical or mental health conditions, such as thyroid disorders, menopause, vitamin B12 deficiency, depression, anxiety, work-related stress or relationship difficulties.
“This means that experiencing symptoms linked to dementia does not automatically mean someone has the condition. However, if you or someone close to you is showing signs or symptoms of dementia, it is important to visit a GP to understand what might be causing them.”
If you or someone you know is showing symptoms that resemble dementia, seeking advice from your GP is an important first step.
Credits: Canva
Gonorrhea poses a far more serious challenge than many realise. Over the years, doctors treating the infection have seen their treatment choices steadily shrink. The bacteria responsible, Neisseria gonorrhoeae, has repeatedly adapted to antibiotics, rendering many once-reliable drugs ineffective. As a result, clinicians have been forced to depend heavily on a single injectable medication, a situation that has raised growing concern.
That dependence is becoming increasingly risky. Data from the US Centers for Disease Control and Prevention show that reported cases of gonorrhea, chlamydia, and syphilis have climbed by nearly 90% since 2004. In 2023 alone, the country recorded more than 2.4 million cases of sexually transmitted infections.
This month, however, marked a significant shift. The US Food and Drug Administration approved two new oral antibiotics to treat gonorrhea: zoliflodacin and gepotidacin. These approvals represent the first entirely new gonorrhea treatments in more than three decades.
“These approvals mark a significant milestone for treatment options for patients with uncomplicated urogenital gonorrhea,” said Dr Adam Sherwat of the FDA in an official statement.
If left untreated, gonorrhea can lead to serious complications, including pelvic inflammatory disease, infertility, and in rare cases, infections that spread to the joints or bloodstream, as per Cleveland Clinic. Many people experience no symptoms at all, allowing the infection to spread quietly. Despite years of research, there is still no licensed vaccine, leaving antibiotics as the primary line of defence.
The newly approved treatments offer a fresh sense of hope. Zoliflodacin, developed by the nonprofit Global Antibiotic Research and Development Partnership in collaboration with Innoviva Specialty Therapeutics, is designed as a single-dose oral medication. Gepotidacin, developed by GSK, is taken in two doses and is also approved for treating certain urinary tract infections.
Both medicines eliminate the need for injections, a shift that could make treatment simpler and more accessible, particularly in settings where access to clinics is limited.
As per Medscape, clinical trial results for both drugs have been encouraging. Zoliflodacin was tested in a large international study involving more than 900 participants across Europe, Africa, Asia, and the US. The drug successfully cured about 90.9% of patients, a rate comparable to the 96.2% success rate of the current injectable standard. Most reported side effects were mild.
Gepotidacin showed similarly strong results in a separate Phase 3 trial that included around 600 patients from six countries. The cure rate reached 92.6%. Some participants reported digestive issues, but these effects were generally described as mild.
Importantly, both medications were effective against strains of gonorrhea that no longer respond to older antibiotics. That said, public health experts stress that these drugs are not a permanent solution.
“Bacteria are smart. They can pass resistant mechanisms between each other,” said Dr Manica Balasegaram of the Global Antibiotic Research and Development Partnership, speaking to CNN.
Several uncertainties remain. Neither drug has yet shown strong effectiveness against throat infections, known as pharyngeal gonorrhea, which are more difficult to detect and treat. There is also ongoing debate about how best to use the new medications. Some experts argue they should be reserved as last-line treatments, while others believe earlier use could help slow resistance.
Dr Tereza Kasaeva of the World Health Organization described the approvals as “an important and timely development” amid rising global infection rates and limited treatment options, according to The Guardian.
For now, the new drugs provide much-needed breathing room. Whether that progress holds will depend on careful prescribing and close monitoring of how resistance evolves.
© 2024 Bennett, Coleman & Company Limited